This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of California, San Francisco Identifier:
First received: February 15, 2008
Last updated: October 16, 2014
Last verified: October 2014

RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving irinotecan together with temozolomide and to see how well it works in treating patients with breast cancer who have received previous treatment for brain metastases.

Condition Intervention Phase
Breast Cancer Metastatic Cancer Drug: irinotecan hydrochloride Drug: temozolomide Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brian Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Objective response rate (percentage of patients with complete or partial response) in the CNS at ≥ 16 weeks [ Time Frame: At least 16 weeks, up to one year ]

Enrollment: 30
Study Start Date: February 2005
Study Completion Date: January 2014
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: irinotecan and temozolomide Drug: irinotecan hydrochloride Drug: temozolomide

Detailed Description:



  • To evaluate the objective response rate systemically and in the CNS to the combination of irinotecan hydrochloride and temozolomide among patients with breast cancer and progressive brain metastases that have progressed after previous treatment for brain metastases.
  • To determine the toxicities associated with the combination of irinotecan hydrochloride and temozolomide in breast cancer patients with progressive brain metastases.


  • To evaluate the time to first progression at any site (CNS or extra-CNS) in patients treated with the combination of irinotecan hydrochloride and temozolomide.
  • To evaluate the overall survival of patients treated with the combination of irinotecan hydrochloride and temozolomide for brain metastases.

OUTLINE: Patients receive irinotecan IV on days 1 and 15 and oral temozolomide on days 1-7 and 15-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed every 4 weeks.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain

    • Extracranial metastases allowed
  • Must have demonstrated progression of brain metastases after prior treatment for brain metastases, including any of the following:

    • External beam radiotherapy
    • Brachytherapy
    • Stereotactic radiosurgery
    • Surgery
    • Chemotherapy
    • Treatments with investigational drugs, biologics, or devices
  • Disease progression in the CNS must meet ≥ 1 of the following criteria:

    • New lesions in the CNS on an imaging study (contrast-enhanced CT scan or MRI)
    • Progressive lesions on an imaging study (contrast-enhanced CT scan or MRI)
  • New or progressive lesions that do not meet measurable disease definition allowed
  • Leptomeningeal disease allowed if concurrent progression or parenchymal brain metastases
  • Not a candidate for surgical resection and/or further stereotactic radiosurgery
  • Hormone receptor status not specified


  • Menopausal status not specified
  • ECOG performance status 0-2
  • Life expectancy ≥ 1 month
  • Hemoglobin ≥ 10 g/dL (transfusion allowed)
  • ANC ≥ 1,500/mm³
  • Granulocyte count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Creatinine ≤ 1.5 mg/dL
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 3 times ULN
  • Must be able to swallow and retain oral medications
  • No other active malignancy except for any of the following:

    • Curatively treated basal or squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Other malignancies considered disease-free
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of immediate or delayed-type hypersensitivity reaction to gadolinium contrast agents or other contraindication to gadolinium contrast
  • No other known contraindication to MRI including, but not limited to, any of the following:

    • Cardiac pacemaker
    • Implanted cardiac defibrillator
    • Brain aneurysm clips
    • Cochlear implant
    • Ocular foreign body
    • Shrapnel
  • No active or uncontrolled infection


  • See Disease Characteristics
  • Recovered from the side effects of prior chemotherapy, surgery, or radiotherapy for extracranial disease or brain metastases
  • Concurrent trastuzumab, bisphosphonate, and/or corticosteroid therapy allowed
  • At least 1 week since prior or on current stable dose of corticosteroid therapy
  • Patients on an enzyme-inducing anti-epileptic agent (EIAE) or valproic acid are eligible if they are switched to an alternate non-EIAE medication
  • Concurrent coumadin allowed
  • No prophylactic use of filgrastim (G-CSF) during first course of treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00617539

United States, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
Sponsors and Collaborators
University of California, San Francisco
National Cancer Institute (NCI)
Principal Investigator: Michelle Melisko, MD University of California, San Francisco
  More Information

Responsible Party: University of California, San Francisco Identifier: NCT00617539     History of Changes
Other Study ID Numbers: CDR0000583265
Study First Received: February 15, 2008
Last Updated: October 16, 2014

Keywords provided by University of California, San Francisco:
recurrent breast cancer
stage IV breast cancer
male breast cancer
tumors metastatic to brain

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasm Metastasis
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents processed this record on September 21, 2017